IN2014DN08199A - - Google Patents
Info
- Publication number
- IN2014DN08199A IN2014DN08199A IN8199DEN2014A IN2014DN08199A IN 2014DN08199 A IN2014DN08199 A IN 2014DN08199A IN 8199DEN2014 A IN8199DEN2014 A IN 8199DEN2014A IN 2014DN08199 A IN2014DN08199 A IN 2014DN08199A
- Authority
- IN
- India
- Prior art keywords
- cxcl13
- subject
- effective amount
- inhibits
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Methods for treating diseases associated with CXCL13 expression including certain autoimmune and inflammatory diseases such as Sjogren's syndrome are provided herein. The methods comprise administering to a subject in need thereof an effective amount of an agent that inhibits CXCL13 activity. According to aspects of the invention illustrated herein there is provided a method of treating preventing or reducing the exacerbation of a B cell mediated inflammatory condition in a subject including administering to a subject an effective amount of an isolated binding molecule which specifically binds to CXCL13 wherein said molecule prevents or inhibits CXCL13 activity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261606049P | 2012-03-02 | 2012-03-02 | |
PCT/US2013/028602 WO2013130959A1 (en) | 2012-03-02 | 2013-03-01 | Methods for the treatment of b cell-mediated inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN08199A true IN2014DN08199A (en) | 2015-05-01 |
Family
ID=47844534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN8199DEN2014 IN2014DN08199A (en) | 2012-03-02 | 2013-03-01 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9890213B2 (en) |
EP (1) | EP2820045B1 (en) |
JP (1) | JP6193275B2 (en) |
KR (1) | KR102090969B1 (en) |
CN (1) | CN104520323B (en) |
AU (1) | AU2013225812B2 (en) |
CA (1) | CA2865928C (en) |
IN (1) | IN2014DN08199A (en) |
NZ (1) | NZ629828A (en) |
WO (1) | WO2013130959A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108912228B (en) | 2009-05-08 | 2022-03-15 | 瓦西尼斯公司 | anti-CD 100 antibodies and methods of use thereof |
NZ608318A (en) | 2010-09-02 | 2015-03-27 | Vaccinex Inc | Anti-cxcl13 antibodies and methods of using the same |
EA029023B1 (en) | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
AU2014212206B2 (en) | 2013-01-31 | 2018-10-18 | Vaccinex, Inc. | Methods for increasing immunoglobulin A levels |
MX2015017485A (en) | 2013-06-25 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases. |
RU2759846C2 (en) | 2016-04-22 | 2021-11-18 | Вэксинекс, Инк. | Display of an integral membrane protein on extracellular enveloped poxvirus virions |
WO2018026715A1 (en) | 2016-08-02 | 2018-02-08 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
JP7256116B2 (en) * | 2016-09-19 | 2023-04-11 | アイ-エムエービー バイオファーマ (ハンジョウ) カンパニー リミテッド | ANTI-GM-CSF ANTIBODY AND USES THEREOF |
MX2021002605A (en) * | 2018-09-18 | 2021-07-21 | I Mab Biopharma Us Ltd | Anti-cxcl13 antibodies for treating autoimmune diseases and cancer. |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
DE68921982T4 (en) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | COUPLING AGENTS AND STERICALLY DISABLED CONJUGATES THEREOF. |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
DE69029036T2 (en) | 1989-06-29 | 1997-05-22 | Medarex Inc | SPECIFIC REAGENTS FOR AIDS THERAPY |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DE69120146T2 (en) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
CA2078689C (en) | 1990-03-20 | 2003-02-11 | Sherie L. Morrison | Chimeric antibodies with receptor binding ligands in place of their constant region |
ES2129029T5 (en) | 1990-10-05 | 2005-10-16 | Celldex Therapeutics, Inc. | DIRECT IMMUNOSTIMULATION WITH BISPECIFIC REAGENTS. |
AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
EP0574395B1 (en) | 1990-11-09 | 2002-06-12 | GILLIES, Stephen D. | Cytokine immunoconjugates |
DE69214709T2 (en) | 1991-04-26 | 1997-02-20 | Surface Active Ltd | New antibodies and methods of using them |
FR2686087A1 (en) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | NOVEL LYMPHOCYTATIC ANTIGEN, CORRESPONDING ANTIBODIES AND THEIR APPLICATIONS. |
EP0627940B1 (en) | 1992-03-05 | 2003-05-07 | Board of Regents, The University of Texas System | Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors |
US6692920B1 (en) | 1994-12-07 | 2004-02-17 | Incyte Corporation | Antibodies to a chemokine expressed in inflamed adenoid |
US5633149A (en) | 1994-12-07 | 1997-05-27 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding novel chemokine expressed in inflamed adenoid |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
CN1190991A (en) | 1995-06-05 | 1998-08-19 | 人类基因组科学公司 | Human chemokine beta-11 and human chemokine alpha-1 |
WO1998011226A2 (en) | 1996-09-10 | 1998-03-19 | Schering Corporation | Mammalian chemokines, related reagents |
US6852508B1 (en) | 1997-02-28 | 2005-02-08 | Genetics Institute, Llc | Chemokine with amino-terminal modifications |
US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
US6110695A (en) | 1997-12-02 | 2000-08-29 | The Regents Of The University Of California | Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
EP1268554A2 (en) | 2000-03-31 | 2003-01-02 | IPF Pharmaceuticals GmbH | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
GB2361003A (en) | 2000-04-07 | 2001-10-10 | Astrazeneca Ab | Novel compounds |
US7052676B2 (en) | 2000-09-26 | 2006-05-30 | The Regents Of The University Of Michigan | Methods for inhibition of HIV replication using a small molecule inhibitor |
US20020111290A1 (en) | 2000-12-01 | 2002-08-15 | Bernhard Homey | Uses of mammalian genes and related reagents |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
US6818406B2 (en) | 2001-03-23 | 2004-11-16 | Mayo Foundation For Medical Education And Research | Rheumatoid arthritis markers |
US7442512B2 (en) | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7413866B2 (en) | 2001-11-30 | 2008-08-19 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2003232456B2 (en) | 2002-05-30 | 2009-06-04 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
EP2322202A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune diseases |
AU2003291549A1 (en) | 2002-11-15 | 2004-06-15 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
US7964194B2 (en) | 2002-11-15 | 2011-06-21 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation |
WO2004047728A2 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2005028511A2 (en) | 2003-03-28 | 2005-03-31 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
CN1972958B (en) | 2004-04-12 | 2013-01-23 | 美国政府卫生与公共服务部 | Method of using adenoviral vectors to induce an immune response |
CA2501422C (en) | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
ATE486610T1 (en) | 2004-07-09 | 2010-11-15 | Chugai Pharmaceutical Co Ltd | ANTI-GLYPICAN-3 ANTIBODIES |
JP2008526205A (en) | 2004-12-31 | 2008-07-24 | ジェネンテック・インコーポレーテッド | Polypeptides that bind to BR3 and uses thereof |
CA2605024C (en) | 2005-04-15 | 2018-05-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
WO2006117910A1 (en) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | Monoclonal antibody against platelet membrane glycoprotein vi |
WO2007064911A1 (en) | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
GB0607774D0 (en) * | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
WO2007124414A2 (en) | 2006-04-21 | 2007-11-01 | Centocor, Inc. | Cxcl13 antagonists and their use for the treatment of inflammatory diseases |
US20080227704A1 (en) | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
US20080199481A1 (en) * | 2007-02-21 | 2008-08-21 | Astrazeneca Ab | Compounds |
CA2682666A1 (en) * | 2007-03-30 | 2008-10-09 | Centocor Ortho Biotech Inc. | Cxcl13 antagonists and their use for the treatment of inflammatory diseases |
WO2010053547A2 (en) * | 2008-11-04 | 2010-05-14 | Anchor Therapeutics, Inc. | Cxcr5 receptor compounds |
NZ608318A (en) * | 2010-09-02 | 2015-03-27 | Vaccinex Inc | Anti-cxcl13 antibodies and methods of using the same |
US10711056B2 (en) | 2011-12-28 | 2020-07-14 | Novelmed Therapeutics, Inc. | Aglycosylated anti-properdin antibodies |
AU2014212206B2 (en) | 2013-01-31 | 2018-10-18 | Vaccinex, Inc. | Methods for increasing immunoglobulin A levels |
WO2014137355A1 (en) | 2013-03-08 | 2014-09-12 | Vaccinex, Inc. | Anti-cxcl13 antibodies and associated epitope sequences |
-
2013
- 2013-03-01 CA CA2865928A patent/CA2865928C/en active Active
- 2013-03-01 AU AU2013225812A patent/AU2013225812B2/en active Active
- 2013-03-01 CN CN201380022683.4A patent/CN104520323B/en active Active
- 2013-03-01 EP EP13708639.3A patent/EP2820045B1/en active Active
- 2013-03-01 KR KR1020147027747A patent/KR102090969B1/en active IP Right Grant
- 2013-03-01 IN IN8199DEN2014 patent/IN2014DN08199A/en unknown
- 2013-03-01 JP JP2014560085A patent/JP6193275B2/en active Active
- 2013-03-01 NZ NZ629828A patent/NZ629828A/en unknown
- 2013-03-01 US US14/382,410 patent/US9890213B2/en active Active
- 2013-03-01 WO PCT/US2013/028602 patent/WO2013130959A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU2013225812A1 (en) | 2014-09-25 |
US9890213B2 (en) | 2018-02-13 |
JP2015509960A (en) | 2015-04-02 |
EP2820045A1 (en) | 2015-01-07 |
EP2820045B1 (en) | 2018-08-22 |
WO2013130959A1 (en) | 2013-09-06 |
CN104520323B (en) | 2018-05-04 |
CN104520323A (en) | 2015-04-15 |
US20150125467A1 (en) | 2015-05-07 |
AU2013225812B2 (en) | 2017-11-30 |
KR102090969B1 (en) | 2020-03-19 |
JP6193275B2 (en) | 2017-09-06 |
CA2865928A1 (en) | 2013-09-06 |
KR20140138830A (en) | 2014-12-04 |
NZ629828A (en) | 2017-05-26 |
CA2865928C (en) | 2021-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN08199A (en) | ||
WO2016106403A3 (en) | Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21 | |
EA201590880A1 (en) | COMPOSITIONS AND METHODS OF TREATMENT PROTEINOPATHY | |
IN2015KN00414A (en) | ||
MX2018001268A (en) | Combination of pd-1 antagonist with an egfr inhibitor. | |
NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
MX2014004766A (en) | Inhibitors of arginase and their therapeutic applications. | |
MX2020010535A (en) | Methods of treating cancer. | |
MX355648B (en) | Methods for treating conditions associated with masp-2 dependent complement activation. | |
WO2013188813A3 (en) | Novel therapeutics for brain cancer | |
EA201500393A1 (en) | BLUTON TYROSINKINASE INHIBITORS | |
WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
BR112015029386A2 (en) | use of eribulin and lenvatinib as combination therapy for cancer treatment | |
GB2496337A (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases | |
JO3462B1 (en) | Human Antibodies to GFR?3 and methods of use thereof | |
PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
TW201611843A (en) | Methods of treatment with arginine deiminase | |
MX2016005446A (en) | Angiopoietin-based interventions for treating cerebral malaria. | |
MX2019001977A (en) | Methods and compositions for treating multiple sclerosis and related disorders. | |
DK2714888T3 (en) | RECOMBINANT DO | |
PH12015500169A1 (en) | Prediction of treatment response to jak/stat inhibitor | |
EA032271B9 (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
MX2017011018A (en) | Inhibition of olig2 activity. | |
MX366046B (en) | Binding molecules that bind human complement factor c2 and uses thereof. | |
MX343589B (en) | Leukotoxin e/d as a new anti-inflammatory agent and microbicide. |